PSMB5 and cancer: Nilotinib-treated cancer cells exhibited decreased extracellular cGAMP levels and increased protein expression levels of γ-H2A.X, pTBK1, and pIRF3, along with reduced cell viability in the presence of RT, suggesting that nilotinib may have a synergistic effect with RT (Fig. 7d–g).